U.S. Marine and Shipping Stock News

NasdaqGS:KTOS
NasdaqGS:KTOSAerospace & Defense

Kratos Rocket Motor Win And New Director Shape Missile Defense Story

Kratos Defense & Security Solutions (NasdaqGS:KTOS) received a new contract from the U.S. Navy's Naval Surface Warfare Center to produce and deliver advanced Oriole solid rocket motors. The award supports missile defense and hypersonic testing programs that use the Oriole system. Kratos also appointed defense industry veteran David King to its Board of Directors. King brings extensive experience growing defense businesses and overseeing large aerospace programs. For investors watching the...
NasdaqCM:CELC
NasdaqCM:CELCBiotechs

Celcuity’s Priority Review Puts Gedatolisib And Investor Trade Offs In Focus

Celcuity (NasdaqCM:CELC) received FDA Priority Review for its New Drug Application for gedatolisib in advanced breast cancer. The Priority Review follows strong Phase 3 efficacy results from the VIKTORIA-1 trial in HR-positive, HER2-negative breast cancer. An additional Phase 3 readout for the PIK3CA mutant cohort is upcoming and could further influence treatment standards for this patient group. Celcuity focuses on targeted therapies for cancer, with gedatolisib as a key asset in its...
NasdaqGS:RPRX
NasdaqGS:RPRXPharmaceuticals

Royalty Pharma (RPRX) Valuation Check As New AI And Deal-Making Leaders Take Charge

Leadership reshuffle puts technology and deal-making in focus Royalty Pharma (RPRX) has refreshed its senior ranks, naming Lucas Glass as Head of Artificial Intelligence and bringing in Greg Butz as Executive Vice President, Partnering & Investments, while also reinforcing its leadership presence in Asia. See our latest analysis for Royalty Pharma. At a share price of US$46.94, Royalty Pharma has posted a 19.68% 90 day share price return and a 51.83% 1 year total shareholder return, as...
NYSE:CNC
NYSE:CNCHealthcare

Is It Time To Reconsider Centene (CNC) After Its Prolonged Share Price Slide

If you are wondering whether Centene's current share price offers value or just more volatility, it helps to break the story down into what the market has been pricing in and how that compares with fundamentals. The stock closed at US$33.56, with returns of a 5.7% decline over 7 days, a 20.8% decline over 30 days, a 19.7% decline year to date, a 44.3% decline over the last year, a 47.7% decline over 3 years and a 46.9% decline over 5 years. This history sets a very specific backdrop for any...
NasdaqGS:KRYS
NasdaqGS:KRYSBiotechs

Krystal Biotech (KRYS) Valuation Check After Recent Pullback And Mixed Earnings Multiple Signals

Krystal Biotech: Stock Performance Context Krystal Biotech (KRYS) has drawn investor attention after a recent pullback, with the stock showing a 1-day return of a 1.39% decline, a 1-month return of a 5.81% decline, and a 1-year return of 37.57%. See our latest analysis for Krystal Biotech. Recent trading has been choppy, with a 30 day share price return of a 5.81% decline contrasting with a 1 year total shareholder return of 37.56%. This indicates that earlier momentum has cooled in the short...
NYSE:OMF
NYSE:OMFConsumer Finance

AM Best Rating Affirmation Supports OneMain Insurance Strength And Investor Focus

AM Best affirmed the credit ratings and outlook for OneMain Holdings’ insurance subsidiaries, reinforcing its view of their financial strength. The decision reflects AM Best’s current assessment of the subsidiaries’ balance sheet quality, risk management and operating performance. For investors watching OneMain Holdings (NYSE:OMF), this rating affirmation comes alongside a mixed share price record. The stock closed at $53.05, with a 4.0% gain over the past week offsetting a 3.9% decline...
NYSE:LW
NYSE:LWFood

Has The Recent Share Price Slump Created An Opportunity In Lamb Weston Holdings (LW)?

If you are wondering whether Lamb Weston Holdings' current share price reflects its underlying value, this article walks through the key signals you can use to judge that for yourself. The stock most recently closed at US$40.83, with returns of 0.5% over 7 days, a 14.9% decline over 30 days, a 3.5% decline year to date and a 22.1% decline over 1 year, alongside a 57.8% decline over 3 years and a 42.9% decline over 5 years. These moves have kept Lamb Weston on the radar for investors looking...
NYSE:CRK
NYSE:CRKOil and Gas

Will Hosting the Texas Gas Power Hub with NextEra Reshape Comstock Resources' (CRK) Western Haynesville Narrative?

Comstock Resources announced that its Western Haynesville operations in Texas were selected in March 2026 to host the Texas Natural Gas-Fired Power Generation Hub, a U.S.-Japan joint project to be built and operated by NextEra Energy under Japan’s very large US$550 billion investment commitment. This collaboration positions Comstock near the center of a major new demand source for Western Haynesville gas, potentially reshaping its role in U.S. energy infrastructure. We’ll now examine how...
NYSE:BKU
NYSE:BKUBanks

Stronger Quarter And Higher Dividend Might Change The Case For Investing In BankUnited (BKU)

BankUnited’s board has approved a quarterly cash dividend of US$0.33 per common share, a 6% increase from US$0.31, payable on April 30, 2026, to shareholders of record on April 10, 2026. This dividend increase, following a quarter in which BankUnited’s revenue and net interest income exceeded analyst expectations, highlights management’s confidence in the bank’s financial position and its emphasis on cash returns to shareholders. We’ll now examine how the stronger quarter and higher dividend...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

Is It Time To Reassess Collegium Pharmaceutical (COLL) After The Recent Share Price Pullback?

If you are wondering whether Collegium Pharmaceutical's current share price reflects its real worth, this breakdown will help you see what the numbers are actually saying about value. The stock closed at US$33.42, with returns of 13.1% over 1 year and 37.1% over 3 years, but a 26.0% decline over 30 days and 26.6% decline year to date may have changed how investors think about its risk and reward profile. Recent coverage has focused on Collegium Pharmaceutical in the context of its share...
NYSE:MA
NYSE:MADiversified Financial

Is It Time To Reconsider Mastercard (MA) Around US$500 After Mixed Multi Year Returns

Wondering if Mastercard at around US$500 a share is still a quality name at a fair price, or if you would be overpaying for growth that may already be reflected in the stock. The share price closed at US$500.75, with a 2.0% return over the last 7 days, 0.6% over the last 30 days, a year-to-date return of an 11.1% decline, a 9.7% decline over 1 year, and a 41.8% return over both 3 and 5 years. These mixed returns can reflect shifting views on growth potential and risk, with some investors...
NasdaqCM:PCT
NasdaqCM:PCTChemicals

Is PureCycle (PCT) Using EU Grant-Funded ASTRA PP Plant To Recast Its European Growth Narrative?

PureCycle Technologies recently signed a €40 million Innovation Fund grant agreement with the EU’s CINEA to build its ‘ASTRA PP’ polypropylene dissolution recycling facility in Belgium’s Port of Antwerp-Bruges, targeting annual production of 59,000 tonnes of PureFive resin and supporting EU circularity and decarbonization goals. The project is intended to help European customers meet recycled content rules in packaging and end-of-life vehicles, positioning PureCycle as a local supplier of...
NYSE:KTB
NYSE:KTBLuxury

A Look At Kontoor Brands (KTB) Valuation As Wrangler Dr. Scholl’s Capsule Targets Festival Shoppers

Kontoor Brands (KTB) is back in focus after Wrangler partnered with Dr. Scholl’s Shoes on a limited-edition capsule that blends Western themed footwear with a co-branded denim jacket aimed at festival season shoppers. See our latest analysis for Kontoor Brands. Despite the recent brand collaborations, Kontoor Brands’ 1-day share price return of 3.15% and 7-day share price return of 2.43% sit against a 90-day share price return of 7.03% and a 5-year total shareholder return of 64.50%. This...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

A Look At TG Therapeutics (TGTX) Valuation After Its New US$750m Credit Facility With Blue Owl

Why TG Therapeutics’ new credit facility matters for shareholders TG Therapeutics (TGTX) shares are reacting to a fresh financing move after the company entered a new five year, US$750 million senior secured credit facility with funds managed by Blue Owl Capital. For you as a shareholder or potential investor, the key points are the repayment of the prior US$250 million facility, a net US$500 million in non dilutive capital, and access to as much as US$1 billion in total debt capacity at the...
NasdaqGS:GLNG
NasdaqGS:GLNGOil and Gas

Golar LNG Review Weighs Sale Options Against Valuation Gap And Momentum

Golar LNG (NasdaqGS:GLNG) has launched a formal review of options for the business, including a possible sale, merger, asset divestitures, or changes to its corporate structure. The company has appointed Goldman Sachs as financial advisor to support this process. The review aims to assess ways to accelerate growth initiatives and evaluate how the current structure supports long term objectives. For investors watching Golar LNG at a share price of $54.06, the timing of this review follows a...
NYSE:PAYC
NYSE:PAYCProfessional Services

Paycom Awards Highlight Product Strength Workplace Culture And Investor Narrative

Paycom Software (NYSE:PAYC) has been named best software in multiple categories in G2’s Spring 2026 Grid Reports, based on customer reviews. The company was also recognized as a 2026 Platinum Employer on the inaugural Where You Work Matters List. Paycom is reportedly the only firm in its sector to receive the Platinum Employer distinction. Paycom focuses on HR and payroll software, so third party recognition of product quality and customer satisfaction can matter for buyers comparing...
NYSE:OGS
NYSE:OGSGas Utilities

Is It Too Late To Consider Buying ONE Gas (OGS) After Recent Share Price Strength?

Wondering if ONE Gas at around US$85.79 is priced for opportunity or already fully valued? This article walks through the key signals that matter for you. The stock has delivered a 10.8% return year to date and 20.4% over the last year, which sits against a modest 0.5% move over the past month and a 0.4% decline over the last week. Recent coverage has focused on ONE Gas as a regulated gas utility, highlighting its role in providing essential services and the way investors often look to such...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Is It Too Late To Consider Protagonist Therapeutics (PTGX) After A 107% One-Year Surge?

Investors may be wondering whether Protagonist Therapeutics at around US$102 still offers value, or if most of the opportunity is already priced in. The stock has posted returns of 0.5% over the last 7 days, 16.9% over the last 30 days, 17.2% year to date and 106.7% over the last year. This naturally raises questions about how much of the story is already reflected in the share price. Recent news flow around Protagonist Therapeutics has focused on its progress as a biotech name and how the...
NYSE:PCG
NYSE:PCGElectric Utilities

A Look At PG&E (PCG) Valuation After UBS And JPMorgan Upgrades On Wildfire Policy Progress

What triggered fresh attention on PG&E stock? PG&E (PCG) is back on investors’ radar after UBS and JPMorgan issued upbeat research views tied to wildfire policy changes, potential legislation focused on liability, and the company’s recent wildfire prevention track record. See our latest analysis for PG&E. The recent analyst upgrades and regulatory updates around dam safety and emergency planning come after a mixed price pattern, with a 10.15% 90 day share price return and a 52.79% five year...
NYSE:AOS
NYSE:AOSBuilding

A Look At A. O. Smith’s Valuation After Recent Short Term Share Price Weakness

A. O. Smith (AOS) is back on investors’ radar after recent trading left the shares with mixed short term performance, including a 1 day decline and a gain over the past week. See our latest analysis for A. O. Smith. The recent 1 day share price decline of 1.93% and 30 day share price return of negative 15.01% sit against a more muted 1 year total shareholder return of 0.08%. This suggests that shorter term momentum has faded even as longer term outcomes have been relatively flat. If you are...
NasdaqGS:HLNE
NasdaqGS:HLNECapital Markets

Is Hamilton Lane (HLNE) Starting To Look Attractive After A 34% One-Year Share Price Slide?

Wondering if Hamilton Lane at around US$97.53 is starting to look interesting on value, or if the market is still pricing in too much optimism. The stock is down 3.4% over the past week, 4.1% over the past month and has fallen 28.6% year to date and 34.2% over the last year, even though the 3 year and 5 year returns sit at 43.7% and 16.9% respectively. Recent headlines have focused on Hamilton Lane's role in private markets and its position in the broader capital markets space. This helps...
NasdaqGS:CHDN
NasdaqGS:CHDNHospitality

Is It Time To Reassess Churchill Downs (CHDN) After Its Recent Share Price Slide?

If you are wondering whether Churchill Downs at around US$87.57 is a bargain or a value trap, you are in the right place for a closer look at what that price might really represent. The stock has recently shown mixed momentum, with a 4.6% gain over the last 7 days contrasting with an 8.9% decline over 30 days and a 21.0% drop over the past year. Recent coverage of Churchill Downs has focused on its role as a long established name in racing and gaming, and ongoing interest in how its assets...